FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea - BioSpace

FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea  BioSpace

LOUISVILLE, Ky., Aug. 26, 2019 /PRNewswire/ -- US WorldMeds, LLC announced today that the U.S. Food and Drug Administration (FDA) approved the ...



Comments

Popular posts from this blog